Current status, problems, and perspectives of non-alcoholic fatty liver disease research
|
摘要
Non-alcoholic fatty liver disease(NAFLD) is a major chronic liver disease that can lead to liver cirrhosis, liver cancer, and ultimately death. NAFLD is pathologically classified as non-alcoholic fatty liver(NAFL) or non-alcoholic steatohepatitis(NASH) based on the existence of ballooned hepatocytes,although the states have been known to transform into each other. Moreover,since the detection of ballooned hepatocytes may be difficult with limited biopsied specimens, its clinical significance needs reconsideration. Repeated liver biopsy to assess histological NAFLD activity for therapeutic response is also impractical, creating the need for body fluid biomarkers and less invasive imaging modalities. Recent longitudinal observational studies have emphasized the importance of advanced fibrosis as a determinant of NAFLD outcome. Thus,identifying predictors of fibrosis progression and developing better screening methods will enable clinicians to isolate high-risk NAFLD patients requiring early intensive intervention. Despite the considerable heterogeneity of NAFLD with regard to underlying disease, patient age, and fibrosis stage, several clinical trials are underway to develop a first-in-class drug. In this review, we summarize the present status and future direction of NAFLD/NASH research towards solving unmet medical needs.
Non-alcoholic fatty liver disease(NAFLD) is a major chronic liver disease that can lead to liver cirrhosis, liver cancer, and ultimately death. NAFLD is pathologically classified as non-alcoholic fatty liver(NAFL) or non-alcoholic steatohepatitis(NASH) based on the existence of ballooned hepatocytes,although the states have been known to transform into each other. Moreover,since the detection of ballooned hepatocytes may be difficult with limited biopsied specimens, its clinical significance needs reconsideration. Repeated liver biopsy to assess histological NAFLD activity for therapeutic response is also impractical, creating the need for body fluid biomarkers and less invasive imaging modalities. Recent longitudinal observational studies have emphasized the importance of advanced fibrosis as a determinant of NAFLD outcome. Thus,identifying predictors of fibrosis progression and developing better screening methods will enable clinicians to isolate high-risk NAFLD patients requiring early intensive intervention. Despite the considerable heterogeneity of NAFLD with regard to underlying disease, patient age, and fibrosis stage, several clinical trials are underway to develop a first-in-class drug. In this review, we summarize the present status and future direction of NAFLD/NASH research towards solving unmet medical needs.
Non-alcoholic fatty liver disease(NAFLD) is a major chronic liver disease that can lead to liver cirrhosis, liver cancer, and ultimately death. NAFLD is pathologically classified as non-alcoholic fatty liver(NAFL) or non-alcoholic steatohepatitis(NASH) based on the existence of ballooned hepatocytes,although the states have been known to transform into each other. Moreover,since the detection of ballooned hepatocytes may be difficult with limited biopsied specimens, its clinical significance needs reconsideration. Repeated liver biopsy to assess histological NAFLD activity for therapeutic response is also impractical, creating the need for body fluid biomarkers and less invasive imaging modalities. Recent longitudinal observational studies have emphasized the importance of advanced fibrosis as a determinant of NAFLD outcome. Thus,identifying predictors of fibrosis progression and developing better screening methods will enable clinicians to isolate high-risk NAFLD patients requiring early intensive intervention. Despite the considerable heterogeneity of NAFLD with regard to underlying disease, patient age, and fibrosis stage, several clinical trials are underway to develop a first-in-class drug. In this review, we summarize the present status and future direction of NAFLD/NASH research towards solving unmet medical needs.
引文
1 Estes C,Anstee QM,Arias-Loste MT,Bantel H,Bellentani S,Caballeria J,Colombo M,Craxi A,Crespo J,Day CP,Eguchi Y,Geier A,Kondili LA,Kroy DC,Lazarus JV,Loomba R,Manns MP,Marchesini G,Nakajima A,Negro F,Petta S,Ratziu V,Romero-Gomez M,Sanyal A,Schattenberg JM,Tacke F,Tanaka J,Trautwein C,Wei L,Zeuzem S,Razavi H.Modeling NAFLDdisease burden in China,France,Germany,Italy,Japan,Spain,United Kingdom,and United States for the period 2016-2030.J Hepatol 2018;69:896-904[PMID:29886156 DOI:10.1016/j.jhep.2018.05.036]
2 Perumpail BJ,Khan MA,Yoo ER,Cholankeril G,Kim D,Ahmed A.Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.World J Gastroenterol 2017;23:8263-8276[PMID:29307986 DOI:10.3748/wjg.v23.i47.8263]
3 Eguchi Y,Hyogo H,Ono M,Mizuta T,Ono N,Fujimoto K,Chayama K,Saibara T;JSG-NAFLD.Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan:a multicenter large retrospective study.J Gastroenterol2012;47:586-595[PMID:22328022 DOI:10.1007/s00535-012-0533-z]
4 Zhu JZ,Zhou QY,Wang YM,Dai YN,Zhu J,Yu CH,Li YM.Prevalence of fatty liver disease and the economy in China:A systematic review.World J Gastroenterol 2015;21:5695-5706[PMID:25987797 DOI:10.3748/wjg.v21.i18.5695]
5 Ludwig J,Viggiano TR,McGill DB,Oh BJ.Nonalcoholic steatohepatitis:Mayo Clinic experiences with a hitherto unnamed disease.Mayo Clin Proc 1980;55:434-438[PMID:7382552]
6 Marrero JA,Fontana RJ,Su GL,Conjeevaram HS,Emick DM,Lok AS.NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States.Hepatology 2002;36:1349-1354[PMID:12447858 DOI:10.1053/jhep.2002.36939]
7 Nagaya T,Tanaka N,Komatsu M,Ichijo T,Sano K,Horiuchi A,Joshita S,Umemura T,Matsumoto A,Yoshizawa K,Aoyama T,Kiyosawa K,Tanaka E.Development from simple steatosis to liver cirrhosis and hepatocellular carcinoma:a 27-year follow-up case.Clin JGastroenterol 2008;1:116-121[PMID:26193649 DOI:10.1007/s12328-008-0017-0]
8 Yasui K,Hashimoto E,Komorizono Y,Koike K,Arii S,Imai Y,Shima T,Kanbara Y,Saibara T,Mori T,Kawata S,Uto H,Takami S,Sumida Y,Takamura T,Kawanaka M,Okanoue T;Japan NASH Study Group,Ministry of Health,Labour,and Welfare of Japan.Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma.Clin Gastroenterol Hepatol 2011;9:428-433;quiz e50[PMID:21320639 DOI:10.1016/j.cgh.2011.01.023]
9 Cohen JC,Horton JD,Hobbs HH.Human fatty liver disease:old questions and new insights.Science 2011;332:1519-1523[PMID:21700865 DOI:10.1126/science.1204265]
10 Watanabe S,Hashimoto E,Ikejima K,Uto H,Ono M,Sumida Y,Seike M,Takei Y,Takehara T,Tokushige K,Nakajima A,Yoneda M,Saibara T,Shiota G,Sakaida I,Nakamuta M,Mizuta T,Tsubouchi H,Sugano K,Shimosegawa T.Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.Hepatol Res 2015;45:363-377[PMID:25832328 DOI:10.1111/hepr.12511]
11 Hashimoto E,Tokushige K,Ludwig J.Diagnosis and classification of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis:Current concepts and remaining challenges.Hepatol Res 2015;45:20-28[PMID:24661406 DOI:10.1111/hepr.12333]
12 Sakamoto M,Tsujikawa H,Effendi K,Ojima H,Harada K,Zen Y,Kondo F,Nakano M,Kage M,Sumida Y,Hashimoto E,Yamada G,Okanoue T,Koike K.Pathological findings of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease.Pathol Int 2017;67:1-7[PMID:27995687 DOI:10.1111/pin.12485]
13 Younossi ZM,Koenig AB,Abdelatif D,Fazel Y,Henry L,Wymer M.Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence,incidence,and outcomes.Hepatology 2016;64:73-84[PMID:26707365 DOI:10.1002/hep.28431]
14 Heianza Y,Arase Y,Tsuji H,Fujihara K,Saito K,Hsieh SD,Tanaka S,Kodama S,Hara S,Sone H.Metabolically healthy obesity,presence or absence of fatty liver,and risk of type 2 diabetes in Japanese individuals:Toranomon Hospital Health Management Center Study 20(TOPICS 20).JClin Endocrinol Metab 2014;99:2952-2960[PMID:24823457 DOI:10.1210/jc.2013-4427]
15 Tsuruta G,Tanaka N,Hongo M,Komatsu M,Horiuchi A,Hamamoto K,Iguchi C,Nakayama Y,Umemura T,Ichijo T,Matsumoto A,Yoshizawa K,Aoyama T,Tanaka E.Nonalcoholic fatty liver disease in Japanese junior high school students:its prevalence and relationship to lifestyle habits.J Gastroenterol 2010;45:666-672[PMID:20084525 DOI:10.1007/s00535-009-0198-4]
16 Berentzen TL,Gamborg M,Holst C,S?rensen TI,Baker JL.Body mass index in childhood and adult risk of primary liver cancer.J Hepatol 2014;60:325-330[PMID:24076363 DOI:10.1016/j.jhep.2013.09.015]
17 Buzzetti E,Pinzani M,Tsochatzis EA.The multiple-hit pathogenesis of non-alcoholic fatty liver disease(NAFLD).Metabolism 2016;65:1038-1048[PMID:26823198 DOI:10.1016/j.metabol.2015.12.012]
18 Tanaka N,Aoyama T,Kimura S,Gonzalez FJ.Targeting nuclear receptors for the treatment of fatty liver disease.Pharmacol Ther 2017;179:142-157[PMID:28546081 DOI:10.1016/j.pharmthera.2017.05.011]
19 Matsusue K,Kusakabe T,Noguchi T,Takiguchi S,Suzuki T,Yamano S,Gonzalez FJ.Hepatic steatosis in leptin-deficient mice is promoted by the PPARgamma target gene Fsp27.Cell Metab2008;7:302-311[PMID:18396136 DOI:10.1016/j.cmet.2008.03.003]
20 Donnelly KL,Smith CI,Schwarzenberg SJ,Jessurun J,Boldt MD,Parks EJ.Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease.JClin Invest 2005;115:1343-1351[PMID:15864352 DOI:10.1172/JCI23621]
21 Tanaka N,Takahashi S,Matsubara T,Jiang C,Sakamoto W,Chanturiya T,Teng R,Gavrilova O,Gonzalez FJ.Adipocyte-specific disruption of fat-specific protein 27 causes hepatosteatosis and insulin resistance in high-fat diet-fed mice.J Biol Chem 2015;290:3092-3105[PMID:25477509DOI:10.1074/jbc.M114.605980]
22 Tanaka N,Takahashi S,Fang ZZ,Matsubara T,Krausz KW,Qu A,Gonzalez FJ.Role of white adipose lipolysis in the development of NASH induced by methionine-and choline-deficient diet.Biochim Biophys Acta 2014;1841:1596-1607[PMID:25178843 DOI:10.1016/j.bbalip.2014.08.015]
23 Safar Zadeh E,Lungu AO,Cochran EK,Brown RJ,Ghany MG,Heller T,Kleiner DE,Gorden P.The liver diseases of lipodystrophy:the long-term effect of leptin treatment.J Hepatol 2013;59:131-137[PMID:23439261 DOI:10.1016/j.jhep.2013.02.007]
24 Rubio-Cabezas O,Puri V,Murano I,Saudek V,Semple RK,Dash S,Hyden CS,Bottomley W,Vigouroux C,MagréJ,Raymond-Barker P,Murgatroyd PR,Chawla A,Skepper JN,Chatterjee VK,Suliman S,Patch AM,Agarwal AK,Garg A,Barroso I,Cinti S,Czech MP,Argente J,O’Rahilly S,Savage DB;LD Screening Consortium.Partial lipodystrophy and insulin resistant diabetes in a patient with a homozygous nonsense mutation in CIDEC.EMBO Mol Med 2009;1:280-287[PMID:20049731 DOI:10.1002/emmm.200900037]
25 Tanaka N,Takahashi S,Zhang Y,Krausz KW,Smith PB,Patterson AD,Gonzalez FJ.Role of fibroblast growth factor 21 in the early stage of NASH induced by methionine-and cholinedeficient diet.Biochim Biophys Acta 2015;1852:1242-1252[PMID:25736301 DOI:10.1016/j.bbadis.2015.02.012]
26 Tanaka N,Takahashi S,Hu X,Lu Y,Fujimori N,Golla S,Fang ZZ,Aoyama T,Krausz KW,Gonzalez FJ.Growth arrest and DNA damage-inducible 45αprotects against nonalcoholic steatohepatitis induced by methionine-and choline-deficient diet.Biochim Biophys Acta Mol Basis Dis 2017;1863:3170-3182[PMID:28844958 DOI:10.1016/j.bbadis.2017.08.017]
27 Akazawa Y,Nakao K.To die or not to die:death signaling in nonalcoholic fatty liver disease.JGastroenterol 2018;53:893-906[PMID:29574534 DOI:10.1007/s00535-018-1451-5]
28 Jiang C,Xie C,Li F,Zhang L,Nichols RG,Krausz KW,Cai J,Qi Y,Fang ZZ,Takahashi S,Tanaka N,Desai D,Amin SG,Albert I,Patterson AD,Gonzalez FJ.Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.J Clin Invest 2015;125:386-402[PMID:25500885 DOI:10.1172/JCI76738]
29 Gan LT,Van Rooyen DM,Koina ME,McCuskey RS,Teoh NC,Farrell GC.Hepatocyte free cholesterol lipotoxicity results from JNK1-mediated mitochondrial injury and is HMGB1 and TLR4-dependent.J Hepatol 2014;61:1376-1384[PMID:25064435 DOI:10.1016/j.jhep.2014.07.024]
30 Zhang L,Nichols RG,Correll J,Murray IA,Tanaka N,Smith PB,Hubbard TD,Sebastian A,Albert I,Hatzakis E,Gonzalez FJ,Perdew GH,Patterson AD.Persistent Organic Pollutants Modify Gut Microbiota-Host Metabolic Homeostasis in Mice Through Aryl Hydrocarbon Receptor Activation.Environ Health Perspect 2015;123:679-688[PMID:25768209 DOI:10.1289/ehp.1409055]
31 Chu H,Duan Y,Yang L,Schnabl B.Small metabolites,possible big changes:a microbiotacentered view of non-alcoholic fatty liver disease.Gut 2018[PMID:30171065 DOI:10.1136/gutjnl-2018-316307]
32 Lee YA,Wallace MC,Friedman SL.Pathobiology of liver fibrosis:a translational success story.Gut 2015;64:830-841[PMID:25681399 DOI:10.1136/gutjnl-2014-306842]
33 Saitta C,Tripodi G,Barbera A,Bertuccio A,Smedile A,Ciancio A,Raffa G,Sangiovanni A,Navarra G,Raimondo G,Pollicino T.Hepatitis B virus(HBV)DNA integration in patients with occult HBV infection and hepatocellular carcinoma.Liver Int 2015;35:2311-2317[PMID:25677098 DOI:10.1111/liv.12807]
34 Kimura T,Kobayashi A,Tanaka N,Sano K,Komatsu M,Fujimori N,Yamazaki T,Shibata S,Ichikawa Y,Joshita S,Umemura T,Matsumoto A,Horiuchi A,Mori H,Wada S,Kiyosawa K,Miyagawa SI,Tanaka E.Clinicopathological characteristics of non-B non-C hepatocellular carcinoma without past hepatitis B virus infection.Hepatol Res 2017;47:405-418[PMID:27288988DOI:10.1111/hepr.12762]
35 Wong CR,Nguyen MH,Lim JK.Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease.World J Gastroenterol 2016;22:8294-8303[PMID:27729736 DOI:10.3748/wjg.v22.i37.8294]
36 Younes R,Bugianesi E.Should we undertake surveillance for HCC in patients with NAFLD?JHepatol 2018;68:326-334[PMID:29122695 DOI:10.1016/j.jhep.2017.10.006]
37 Tanaka N,Horiuchi A,Yokoyama T,Kaneko G,Horigome N,Yamaura T,Nagaya T,Komatsu M,Sano K,Miyagawa S,Aoyama T,Tanaka E.Clinical characteristics of de novo nonalcoholic fatty liver disease following pancreaticoduodenectomy.J Gastroenterol 2011;46:758-768[PMID:21267748 DOI:10.1007/s00535-011-0370-5]
38 Nagaya T,Tanaka N,Kimura T,Kitabatake H,Fujimori N,Komatsu M,Horiuchi A,Yamaura T,Umemura T,Sano K,Gonzalez FJ,Aoyama T,Tanaka E.Mechanism of the development of nonalcoholic steatohepatitis after pancreaticoduodenectomy.BBA Clin 2015;3:168-174[PMID:26674248 DOI:10.1016/j.bbacli.2015.02.001]
39 Tanaka N,Yazaki M,Kobayashi K.A lean man with nonalcoholic fatty liver disease.Clin Gastroenterol Hepatol 2007;5:A32[PMID:16901765 DOI:10.1016/j.cgh.2006.06.014]
40 Komatsu M,Yazaki M,Tanaka N,Sano K,Hashimoto E,Takei Y,Song YZ,Tanaka E,Kiyosawa K,Saheki T,Aoyama T,Kobayashi K.Citrin deficiency as a cause of chronic liver disorder mimicking non-alcoholic fatty liver disease.J Hepatol 2008;49:810-820[PMID:18620775 DOI:10.1016/j.jhep.2008.05.016]
41 Komatsu M,Kimura T,Yazaki M,Tanaka N,Yang Y,Nakajima T,Horiuchi A,Fang ZZ,Joshita S,Matsumoto A,Umemura T,Tanaka E,Gonzalez FJ,Ikeda S,Aoyama T.Steatogenesis in adultonset type II citrullinemia is associated with down-regulation of PPARα.Biochim Biophys Acta2015;1852:473-481[PMID:25533124 DOI:10.1016/j.bbadis.2014.12.011]
42 Pericleous M,Kelly C,Wang T,Livingstone C,Ala A.Wolman’s disease and cholesteryl ester storage disorder:the phenotypic spectrum of lysosomal acid lipase deficiency.Lancet Gastroenterol Hepatol 2017;2:670-679[PMID:28786388 DOI:10.1016/S2468-1253(17)30052-3]
43 Tanaka N,Tanaka E,Sheena Y,Komatsu M,Okiyama W,Misawa N,Muto H,Umemura T,Ichijo T,Matsumoto A,Yoshizawa K,Horiuchi A,Kiyosawa K.Useful parameters for distinguishing nonalcoholic steatohepatitis with mild steatosis from cryptogenic chronic hepatitis in the Japanese population.Liver Int 2006;26:956-963[PMID:16953836 DOI:10.1111/j.1478-3231.2006.01338.x]
44 Kimura T,Tanaka N,Fujimori N,Sugiura A,Yamazaki T,Joshita S,Komatsu M,Umemura T,Matsumoto A,Tanaka E.Mild drinking habit is a risk factor for hepatocarcinogenesis in nonalcoholic fatty liver disease with advanced fibrosis.World J Gastroenterol 2018;24:1440-1450[PMID:29632425 DOI:10.3748/wjg.v24.i13.1440]
45 Li Q,Dhyani M,Grajo JR,Sirlin C,Samir AE.Current status of imaging in nonalcoholic fatty liver disease.World J Hepatol 2018;10:530-542[PMID:30190781 DOI:10.4254/wjh.v10.i8.530]
46 Zhang YN,Fowler KJ,Hamilton G,Cui JY,Sy EZ,Balanay M,Hooker JC,Szeverenyi N,Sirlin CB.Liver fat imaging-a clinical overview of ultrasound,CT,and MR imaging.Br J Radiol 2018;91:20170959[PMID:29722568 DOI:10.1259/bjr.20170959]
47 Hatta T,Fujinaga Y,Kadoya M,Ueda H,Murayama H,Kurozumi M,Ueda K,Komatsu M,Nagaya T,Joshita S,Kodama R,Tanaka E,Uehara T,Sano K,Tanaka N.Accurate and simple method for quantification of hepatic fat content using magnetic resonance imaging:a prospective study in biopsy-proven nonalcoholic fatty liver disease.J Gastroenterol 2010;45:1263-1271[PMID:20625773 DOI:10.1007/s00535-010-0277-6]
48 Fujimori N,Tanaka N,Shibata S,Sano K,Yamazaki T,Sekiguchi T,Kitabatake H,Ichikawa Y,Kimura T,Komatsu M,Umemura T,Matsumoto A,Tanaka E.Controlled attenuation parameter is correlated with actual hepatic fat content in patients with non-alcoholic fatty liver disease with none-to-mild obesity and liver fibrosis.Hepatol Res 2016;46:1019-1027[PMID:27183219 DOI:10.1111/hepr.12649]
49 Tanaka N,Ichijo T,Okiyama W,Mutou H,Misawa N,Matsumoto A,Yoshizawa K,Tanaka E,Kiyosawa K.Laparoscopic findings in patients with nonalcoholic steatohepatitis.Liver Int 2006;26:32-38[PMID:16420508 DOI:10.1111/j.1478-3231.2005.01198.x]
50 Brunt EM.Nonalcoholic fatty liver disease and the ongoing role of liver biopsy evaluation.Hepatol Commun 2017;1:370-378[PMID:29404465 DOI:10.1002/hep4.1055]
51 Tsutsui M,Tanaka N,Kawakubo M,Sheena Y,Horiuchi A,Komatsu M,Nagaya T,Joshita S,Umemura T,Ichijo T,Matsumoto A,Yoshizawa K,Aoyama T,Tanaka E,Sano K.Serum fragmented cytokeratin 18 levels reflect the histologic activity score of nonalcoholic fatty liver disease more accurately than serum alanine aminotransferase levels.J Clin Gastroenterol 2010;44:440-447[PMID:20104187 DOI:10.1097/MCG.0b013e3181bdefe2]
52 Tanaka N,Matsubara T,Krausz KW,Patterson AD,Gonzalez FJ.Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis.Hepatology 2012;56:118-129[PMID:22290395 DOI:10.1002/hep.25630]
53 Matsubara T,Tanaka N,Krausz KW,Manna SK,Kang DW,Anderson ER,Luecke H,Patterson AD,Shah YM,Gonzalez FJ.Metabolomics identifies an inflammatory cascade involved in dioxin-and diet-induced steatohepatitis.Cell Metab 2012;16:634-644[PMID:23140643 DOI:10.1016/j.cmet.2012.10.006]
54 Kitabatake H,Tanaka N,Fujimori N,Komatsu M,Okubo A,Kakegawa K,Kimura T,Sugiura A,Yamazaki T,Shibata S,Ichikawa Y,Joshita S,Umemura T,Matsumoto A,Koinuma M,Sano K,Aoyama T,Tanaka E.Association between endotoxemia and histological features of nonalcoholic fatty liver disease.World J Gastroenterol 2017;23:712-722[PMID:28216979 DOI:10.3748/wjg.v23.i4.712]
55 Enomoto H,Bando Y,Nakamura H,Nishiguchi S,Koga M.Liver fibrosis markers of nonalcoholic steatohepatitis.World J Gastroenterol 2015;21:7427-7435[PMID:26139988 DOI:10.3748/wjg.v21.i24.7427]
56 Angulo P,Kleiner DE,Dam-Larsen S,Adams LA,Bjornsson ES,Charatcharoenwitthaya P,Mills PR,Keach JC,Lafferty HD,Stahler A,Haflidadottir S,Bendtsen F.Liver Fibrosis,but No Other Histologic Features,Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.Gastroenterology 2015;149:389-397.e10[PMID:25935633 DOI:10.1053/j.gastro.2015.04.043]
57 Loomba R,Chalasani N.The Hierarchical Model of NAFLD:Prognostic Significance of Histologic Features in NASH.Gastroenterology 2015;149:278-281[PMID:26116800 DOI:10.1053/j.gastro.2015.06.016]
58 Yoneda M,Fujii H,Sumida Y,Hyogo H,Itoh Y,Ono M,Eguchi Y,Suzuki Y,Aoki N,Kanemasa K,Imajo K,Chayama K,Saibara T,Kawada N,Fujimoto K,Kohgo Y,Yoshikawa T,Okanoue T;Japan Study Group of Nonalcoholic Fatty Liver Disease.Platelet count for predicting fibrosis in nonalcoholic fatty liver disease.J Gastroenterol 2011;46:1300-1306[PMID:21750883 DOI:10.1007/s00535-011-0436-4]
59 Kaneda H,Hashimoto E,Yatsuji S,Tokushige K,Shiratori K.Hyaluronic acid levels can predict severe fibrosis and platelet counts can predict cirrhosis in patients with nonalcoholic fatty liver disease.J Gastroenterol Hepatol 2006;21:1459-1465[PMID:16911693 DOI:10.1111/j.1440-1746.2006.04447.x]
60 Ogawa Y,Honda Y,Kessoku T,Tomeno W,Imajo K,Yoneda M,Kawanaka M,Kirikoshi H,Ono M,Taguri M,Saito S,Yamanaka T,Wada K,Nakajima A.Wisteria floribunda agglutinin-positive Mac-2-binding protein and type 4 collagen 7S:useful markers for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease.J Gastroenterol Hepatol 2018;33:1795-1803[PMID:29633352 DOI:10.1111/jgh.14156]
61 Kamada T,Ono M,Hyogo H,Fujii H,Sumida Y,Yamada M,Mori K,Tanaka S,Maekawa T,Ebisutani Y,Yamamoto A,Takamatsu S,Yoneda M,Kawada N,Chayama K,Saibara T,Takehara T,Miyoshi E;Japan Study Group of Nonalcoholic Fatty Liver Disease(JSGNAFLD).Use of Mac-2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis.Hepatol Commun2017;1:780-791[PMID:29404494 DOI:10.1002/hep4.1080]
62 Atsukawa M,Tsubota A,Okubo T,Arai T,Nakagawa A,Itokawa N,Kondo C,Kato K,Hatori T,Hano H,Oikawa T,Emoto N,Abe M,Kage M,Iwakiri K.Serum Wisteria floribunda agglutininpositive Mac-2 binding protein more reliably distinguishes liver fibrosis stages in non-alcoholic fatty liver disease than serum Mac-2 binding protein.Hepatol Res 2018;48:424-432[PMID:29274190 DOI:10.1111/hepr.13046]
63 Fujimori N,Umemura T,Kimura T,Tanaka N,Sugiura A,Yamazaki T,Joshita S,Komatsu M,Usami Y,Sano K,Igarashi K,Matsumoto A,Tanaka E.Serum autotaxin levels are correlated with hepatic fibrosis and ballooning in patients with non-alcoholic fatty liver disease.World JGastroenterol 2018;24:1239-1249[PMID:29568204 DOI:10.3748/wjg.v24.i11.1239]
64 Angulo P,Hui JM,Marchesini G,Bugianesi E,George J,Farrell GC,Enders F,Saksena S,Burt AD,Bida JP,Lindor K,Sanderson SO,Lenzi M,Adams LA,Kench J,Therneau TM,Day CP.The NAFLD fibrosis score:a noninvasive system that identifies liver fibrosis in patients with NAFLD.Hepatology 2007;45:846-854[PMID:17393509 DOI:10.1002/hep.21496]
65 Peleg N,Issachar A,Sneh-Arbib O,Shlomai A.AST to Platelet Ratio Index and fibrosis 4calculator scores for non-invasive assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease.Dig Liver Dis 2017;49:1133-1138[PMID:28572039 DOI:10.1016/j.dld.2017.05.002]
66 Sumida Y,Yoneda M,Hyogo H,Itoh Y,Ono M,Fujii H,Eguchi Y,Suzuki Y,Aoki N,Kanemasa K,Fujita K,Chayama K,Saibara T,Kawada N,Fujimoto K,Kohgo Y,Yoshikawa T,Okanoue T;Japan Study Group of Nonalcoholic Fatty Liver Disease(JSG-NAFLD).Validation of the FIB4index in a Japanese nonalcoholic fatty liver disease population.BMC Gastroenterol 2012;12:2[PMID:22221544 DOI:10.1186/1471-230X-12-2]
67 Harrison SA,Oliver D,Arnold HL,Gogia S,Neuschwander-Tetri BA.Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease.Gut 2008;57:1441-1447[PMID:18390575 DOI:10.1136/gut.2007.146019]
68 Okanoue T,Ebise H,Kai T,Mizuno M,Shima T,Ichihara J,Aoki M.A simple scoring system using type IV collagen 7S and aspartate aminotransferase for diagnosing nonalcoholic steatohepatitis and related fibrosis.J Gastroenterol 2018;53:129-139[PMID:28589339 DOI:10.1007/s00535-017-1355-9]
69 Guha IN,Parkes J,Roderick P,Chattopadhyay D,Cross R,Harris S,Kaye P,Burt AD,Ryder SD,Aithal GP,Day CP,Rosenberg WM.Noninvasive markers of fibrosis in nonalcoholic fatty liver disease:Validating the European Liver Fibrosis Panel and exploring simple markers.Hepatology2008;47:455-460[PMID:18038452 DOI:10.1002/hep.21984]
70 Ratziu V,Massard J,Charlotte F,Messous D,Imbert-Bismut F,Bonyhay L,Tahiri M,Munteanu M,Thabut D,Cadranel JF,Le Bail B,de Ledinghen V,Poynard T;LIDO Study Group;CYTOLstudy group.Diagnostic value of biochemical markers(FibroTest-FibroSURE)for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease.BMC Gastroenterol 2006;6:6[PMID:16503961 DOI:10.1186/1471-230X-6-6]
71 Sumida Y,Nakajima A,Itoh Y.Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.World JGastroenterol 2014;20:475-485[PMID:24574716 DOI:10.3748/wjg.v20.i2.475]
72 Hsu C,Caussy C,Imajo K,Chen J,Singh S,Kaulback K,Le MD,Hooker J,Tu X,Bettencourt R,Yin M,Sirlin CB,Ehman RL,Nakajima A,Loomba R.Magnetic Resonance vs Transient Elastography Analysis of Patients With Nonalcoholic Fatty Liver Disease:A Systematic Review and Pooled Analysis of Individual Participants.Clin Gastroenterol Hepatol 2018[PMID:29908362DOI:10.1016/j.cgh.2018.05.059]
73 Vilar-Gomez E,Yasells-Garcia A,Martinez-Perez Y,Calzadilla-Bertot L,Torres-Gonzalez A,Gra-Oramas B,Gonzalez-Fabian L,Villa-Jimenez O,Friedman SL,Diago M,Romero-Gomez M.Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention.Hepatology 2016;63:1875-1887[PMID:26849287 DOI:10.1002/hep.28484]
74 Romero-Gómez M,Zelber-Sagi S,Trenell M.Treatment of NAFLD with diet,physical activity and exercise.J Hepatol 2017;67:829-846[PMID:28545937 DOI:10.1016/j.jhep.2017.05.016]
75 Marchesini G,Petta S,Dalle Grave R.Diet,weight loss,and liver health in nonalcoholic fatty liver disease:Pathophysiology,evidence,and practice.Hepatology 2016;63:2032-2043[PMID:26663351 DOI:10.1002/hep.28392]
76 von Sch?nfels W,Beckmann JH,Ahrens M,Hendricks A,R?cken C,Szymczak S,Hampe J,Schafmayer C.Histologic improvement of NAFLD in patients with obesity after bariatric surgery based on standardized NAS(NAFLD activity score).Surg Obes Relat Dis 2018;14:1607-1616[PMID:30146425 DOI:10.1016/j.soard.2018.07.012]
77 Watanabe S,Hashimoto E,Ikejima K,Uto H,Ono M,Sumida Y,Seike M,Takei Y,Takehara T,Tokushige K,Nakajima A,Yoneda M,Saibara T,Shiota G,Sakaida I,Nakamuta M,Mizuta T,Tsubouchi H,Sugano K,Shimosegawa T;Japanese Society of Gastroenterology;Japan Society of Hepatology.Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.J Gastroenterol 2015;50:364-377[PMID:25708290 DOI:10.1007/s00535-015-1050-7]
78 Younossi Z,Tacke F,Arrese M,Sharma BC,Mostafa I,Bugianesi E,Wong VW,Yilmaz Y,George J,Fan J,Vos MB.Global Perspectives on Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis.Hepatology 2018[PMID:30179269 DOI:10.1002/hep.30251]
79 Sanyal AJ,Chalasani N,Kowdley KV,McCullough A,Diehl AM,Bass NM,Neuschwander-Tetri BA,Lavine JE,Tonascia J,Unalp A,Van Natta M,Clark J,Brunt EM,Kleiner DE,Hoofnagle JH,Robuck PR;NASH CRN.Pioglitazone,vitamin E,or placebo for nonalcoholic steatohepatitis.NEngl J Med 2010;362:1675-1685[PMID:20427778 DOI:10.1056/NEJMoa0907929]
80 Cusi K,Orsak B,Bril F,Lomonaco R,Hecht J,Ortiz-Lopez C,Tio F,Hardies J,Darland C,Musi N,Webb A,Portillo-Sanchez P.Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus:A Randomized Trial.Ann Intern Med 2016;165:305-315[PMID:27322798 DOI:10.7326/M15-1774]
81 Huang MY,Chung CH,Chang WK,Lin CS,Chen KW,Hsieh TY,Chien WC,Lin HH.The role of thiazolidinediones in hepatocellular carcinoma risk reduction:a population-based cohort study in Taiwan.Am J Cancer Res 2017;7:1606-1616[PMID:28744408]
82 Portillo-Sanchez P,Bril F,Lomonaco R,Barb D,Orsak B,Bruder JM,Cusi K.Effect of pioglitazone on bone mineral density in patients with nonalcoholic steatohepatitis:A 36-month clinical trial.J Diabetes 2018[PMID:30073778 DOI:10.1111/1753-0407.12833]
83 Sumida Y,Yoneda M.Current and future pharmacological therapies for NAFLD/NASH.JGastroenterol 2018;53:362-376[PMID:29247356 DOI:10.1007/s00535-017-1415-1]
84 Neuschwander-Tetri BA,Loomba R,Sanyal AJ,Lavine JE,Van Natta ML,Abdelmalek MF,Chalasani N,Dasarathy S,Diehl AM,Hameed B,Kowdley KV,McCullough A,Terrault N,Clark JM,Tonascia J,Brunt EM,Kleiner DE,Doo E;NASH Clinical Research Network.Farnesoid Xnuclear receptor ligand obeticholic acid for non-cirrhotic,non-alcoholic steatohepatitis(FLINT):a multicentre,randomised,placebo-controlled trial.Lancet 2015;385:956-965[PMID:25468160DOI:10.1016/S0140-6736(14)61933-4]
85 Ratziu V,Harrison SA,Francque S,Bedossa P,Lehert P,Serfaty L,Romero-Gomez M,Boursier J,Abdelmalek M,Caldwell S,Drenth J,Anstee QM,Hum D,Hanf R,Megnien S,Staels B,Sanyal A;GOLDEN-505 Investigator Study Group.Elafibranor,an Agonist of the Peroxisome Proliferator-Activated Receptor-αand-δ,Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.Gastroenterology 2016;150:1147-1159.e5[PMID:26874076 DOI:10.1053/j.gastro.2016.01.038]
86 Wang PX,Ji YX,Zhang XJ,Zhao LP,Yan ZZ,Zhang P,Shen LJ,Yang X,Fang J,Tian S,Zhu XY,Gong J,Zhang X,Wei QF,Wang Y,Li J,Wan L,Xie Q,She ZG,Wang Z,Huang Z,Li H.Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates.Nat Med 2017;23:439-449[PMID:28218919 DOI:10.1038/nm.4290]
87 Schuster S,Feldstein AE.NASH:Novel therapeutic strategies targeting ASK1 in NASH.Nat Rev Gastroenterol Hepatol 2017;14:329-330[PMID:28377639 DOI:10.1038/nrgastro.2017.42]
88 Friedman SL,Ratziu V,Harrison SA,Abdelmalek MF,Aithal GP,Caballeria J,Francque S,Farrell G,Kowdley KV,Craxi A,Simon K,Fischer L,Melchor-Khan L,Vest J,Wiens BL,Vig P,Seyedkazemi S,Goodman Z,Wong VW,Loomba R,Tacke F,Sanyal A,Lefebvre E.Arandomized,placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis.Hepatology 2018;67:1754-1767[PMID:28833331 DOI:10.1002/hep.29477]
89 Akuta N,Watanabe C,Kawamura Y,Arase Y,Saitoh S,Fujiyama S,Sezaki H,Hosaka T,Kobayashi M,Kobayashi M,Suzuki Y,Suzuki F,Ikeda K,Kumada H.Effects of a sodiumglucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus:Preliminary prospective study based on serial liver biopsies.Hepatol Commun 2017;1:46-52[PMID:29404432 DOI:10.1002/hep4.1019]
90 Sanyal A,Charles ED,Neuschwander-Tetri BA,Loomba R,Harrison SA,Abdelmalek MF,Lawitz EJ,Halegoua-DeMarzio D,Kundu S,Noviello S,Luo Y,Christian R.Pegbelfermin(BMS-986036),a PEGylated fibroblast growth factor 21 analogue,in patients with non-alcoholic steatohepatitis:a randomised,double-blind,placebo-controlled,phase 2a trial.Lancet 2018[PMID:30554783 DOI:10.1016/S0140-6736(18)31785-9]
91 Barreyro FJ,Holod S,Finocchietto PV,Camino AM,Aquino JB,Avagnina A,Carreras MC,Poderoso JJ,Gores GJ.The pan-caspase inhibitor Emricasan(IDN-6556)decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis.Liver Int 2015;35:953-966[PMID:24750664 DOI:10.1111/liv.12570]
92 Harrison SA,Marri SR,Chalasani N,Kohli R,Aronstein W,Thompson GA,Irish W,Miles MV,Xanthakos SA,Lawitz E,Noureddin M,Schiano TD,Siddiqui M,Sanyal A,Neuschwander-Tetri BA,Traber PG.Randomised clinical study:GR-MD-02,a galectin-3 inhibitor,vs.placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis.Aliment Pharmacol Ther2016;44:1183-1198[PMID:27778367 DOI:10.1111/apt.13816]
93 Birukawa NK,Murase K,Sato Y,Kosaka A,Yoneda A,Nishita H,Fujita R,Nishimura M,Ninomiya T,Kajiwara K,Miyazaki M,Nakashima Y,Ota S,Murakami Y,Tanaka Y,Minomi K,Tamura Y,Niitsu Y.Activated hepatic stellate cells are dependent on self-collagen,cleaved by membrane type 1 matrix metalloproteinase for their growth.J Biol Chem 2014;289:20209-20221[PMID:24867951 DOI:10.1074/jbc.M113.544494]
94 Boursier J,Mueller O,Barret M,Machado M,Fizanne L,Araujo-Perez F,Guy CD,Seed PC,Rawls JF,David LA,Hunault G,Oberti F,Calès P,Diehl AM.The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota.Hepatology 2016;63:764-775[PMID:26600078 DOI:10.1002/hep.28356]
95 Da Silva HE,Teterina A,Comelli EM,Taibi A,Arendt BM,Fischer SE,Lou W,Allard JP.Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass index and insulin resistance.Sci Rep 2018;8:1466[PMID:29362454 DOI:10.1038/s41598-018-19753-9]
96 Rau M,Rehman A,Dittrich M,Groen AK,Hermanns HM,Seyfried F,Beyersdorf N,Dandekar T,Rosenstiel P,Geier A.Fecal SCFAs and SCFA-producing bacteria in gut microbiome of human NAFLD as a putative link to systemic T-cell activation and advanced disease.United European Gastroenterol J 2018;6:1496-1507[PMID:30574320 DOI:10.1177/2050640618804444]
97 Yoshimoto S,Loo TM,Atarashi K,Kanda H,Sato S,Oyadomari S,Iwakura Y,Oshima K,Morita H,Hattori M,Honda K,Ishikawa Y,Hara E,Ohtani N.Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome.Nature 2013;499:97-101[PMID:23803760DOI:10.1038/nature12347]
98 Tripathi A,Debelius J,Brenner DA,Karin M,Loomba R,Schnabl B,Knight R.The gut-liver axis and the intersection with the microbiome.Nat Rev Gastroenterol Hepatol 2018;15:397-411[PMID:29748586 DOI:10.1038/s41575-018-0011-z]
99 Alkhouri N,Poordad F,Lawitz E.Management of nonalcoholic fatty liver disease:Lessons learned from type 2 diabetes.Hepatol Commun 2018;2:778-785[PMID:30027137 DOI:10.1002/hep4.1195]
100 Nasr P,Ignatova S,Kechagias S,Ekstedt M.Natural history of nonalcoholic fatty liver disease:Aprospective follow-up study with serial biopsies.Hepatol Commun 2017;2:199-210[PMID:29404527 DOI:10.1002/hep4.1134]
101 Loomba R,Sanyal AJ,Kowdley KV,Terrault N,Chalasani NP,Abdelmalek MF,McCullough AJ,Shringarpure R,Ferguson B,Lee L,Chen J,Liberman A,Shapiro D,Neuschwander-Tetri BA.Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis.Gastroenterology 2019;156:88-95.e5[PMID:30222962 DOI:10.1053/j.gastro.2018.09.021]
102 Eslam M,Hashem AM,Romero-Gomez M,Berg T,Dore GJ,Mangia A,Chan HLY,Irving WL,Sheridan D,Abate ML,Adams LA,Weltman M,Bugianesi E,Spengler U,Shaker O,Fischer J,Mollison L,Cheng W,Nattermann J,Riordan S,Miele L,Kelaeng KS,Ampuero J,Ahlenstiel G,McLeod D,Powell E,Liddle C,Douglas MW,Booth DR,George J;International Liver Disease Genetics Consortium(ILDGC).FibroGENE:A gene-based model for staging liver fibrosis.JHepatol 2016;64:390-398[PMID:26592354 DOI:10.1016/j.jhep.2015.11.008]
103 Tanaka N,Sano K,Horiuchi A,Tanaka E,Kiyosawa K,Aoyama T.Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis.J Clin Gastroenterol 2008;42:413-418[PMID:18277895 DOI:10.1097/MCG.0b013e31815591aa]
104 Sumida Y,Murotani K,Saito M,Tamasawa A,Osonoi Y,Yoneda M,Osonoi T.Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease:A prospective,single-arm trial(LEAD trial).Hepatol Res 2018[PMID:30051943 DOI:10.1111/hepr.13236]
105 Komatsu M,Tanaka N,Kimura T,Fujimori N,Sano K,Horiuchi A,Sugiura A,Yamazaki T,Shibata S,Joshita S,Umemura T,Matsumoto A,Tanaka E.Miglitol attenuates non-alcoholic steatohepatitis in diabetic patients.Hepatol Res 2018;48:1092-1098[PMID:29935004 DOI:10.1111/hepr.13223]
106 Nagaya T,Tanaka N,Suzuki T,Sano K,Horiuchi A,Komatsu M,Nakajima T,Nishizawa T,Joshita S,Umemura T,Ichijo T,Matsumoto A,Yoshizawa K,Nakayama J,Tanaka E,Aoyama T.Down-regulation of SREBP-1c is associated with the development of burned-out NASH.J Hepatol2010;53:724-731[PMID:20655124 DOI:10.1016/j.jhep.2010.04.033]
2 Perumpail BJ,Khan MA,Yoo ER,Cholankeril G,Kim D,Ahmed A.Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.World J Gastroenterol 2017;23:8263-8276[PMID:29307986 DOI:10.3748/wjg.v23.i47.8263]
3 Eguchi Y,Hyogo H,Ono M,Mizuta T,Ono N,Fujimoto K,Chayama K,Saibara T;JSG-NAFLD.Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan:a multicenter large retrospective study.J Gastroenterol2012;47:586-595[PMID:22328022 DOI:10.1007/s00535-012-0533-z]
4 Zhu JZ,Zhou QY,Wang YM,Dai YN,Zhu J,Yu CH,Li YM.Prevalence of fatty liver disease and the economy in China:A systematic review.World J Gastroenterol 2015;21:5695-5706[PMID:25987797 DOI:10.3748/wjg.v21.i18.5695]
5 Ludwig J,Viggiano TR,McGill DB,Oh BJ.Nonalcoholic steatohepatitis:Mayo Clinic experiences with a hitherto unnamed disease.Mayo Clin Proc 1980;55:434-438[PMID:7382552]
6 Marrero JA,Fontana RJ,Su GL,Conjeevaram HS,Emick DM,Lok AS.NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States.Hepatology 2002;36:1349-1354[PMID:12447858 DOI:10.1053/jhep.2002.36939]
7 Nagaya T,Tanaka N,Komatsu M,Ichijo T,Sano K,Horiuchi A,Joshita S,Umemura T,Matsumoto A,Yoshizawa K,Aoyama T,Kiyosawa K,Tanaka E.Development from simple steatosis to liver cirrhosis and hepatocellular carcinoma:a 27-year follow-up case.Clin JGastroenterol 2008;1:116-121[PMID:26193649 DOI:10.1007/s12328-008-0017-0]
8 Yasui K,Hashimoto E,Komorizono Y,Koike K,Arii S,Imai Y,Shima T,Kanbara Y,Saibara T,Mori T,Kawata S,Uto H,Takami S,Sumida Y,Takamura T,Kawanaka M,Okanoue T;Japan NASH Study Group,Ministry of Health,Labour,and Welfare of Japan.Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma.Clin Gastroenterol Hepatol 2011;9:428-433;quiz e50[PMID:21320639 DOI:10.1016/j.cgh.2011.01.023]
9 Cohen JC,Horton JD,Hobbs HH.Human fatty liver disease:old questions and new insights.Science 2011;332:1519-1523[PMID:21700865 DOI:10.1126/science.1204265]
10 Watanabe S,Hashimoto E,Ikejima K,Uto H,Ono M,Sumida Y,Seike M,Takei Y,Takehara T,Tokushige K,Nakajima A,Yoneda M,Saibara T,Shiota G,Sakaida I,Nakamuta M,Mizuta T,Tsubouchi H,Sugano K,Shimosegawa T.Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.Hepatol Res 2015;45:363-377[PMID:25832328 DOI:10.1111/hepr.12511]
11 Hashimoto E,Tokushige K,Ludwig J.Diagnosis and classification of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis:Current concepts and remaining challenges.Hepatol Res 2015;45:20-28[PMID:24661406 DOI:10.1111/hepr.12333]
12 Sakamoto M,Tsujikawa H,Effendi K,Ojima H,Harada K,Zen Y,Kondo F,Nakano M,Kage M,Sumida Y,Hashimoto E,Yamada G,Okanoue T,Koike K.Pathological findings of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease.Pathol Int 2017;67:1-7[PMID:27995687 DOI:10.1111/pin.12485]
13 Younossi ZM,Koenig AB,Abdelatif D,Fazel Y,Henry L,Wymer M.Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence,incidence,and outcomes.Hepatology 2016;64:73-84[PMID:26707365 DOI:10.1002/hep.28431]
14 Heianza Y,Arase Y,Tsuji H,Fujihara K,Saito K,Hsieh SD,Tanaka S,Kodama S,Hara S,Sone H.Metabolically healthy obesity,presence or absence of fatty liver,and risk of type 2 diabetes in Japanese individuals:Toranomon Hospital Health Management Center Study 20(TOPICS 20).JClin Endocrinol Metab 2014;99:2952-2960[PMID:24823457 DOI:10.1210/jc.2013-4427]
15 Tsuruta G,Tanaka N,Hongo M,Komatsu M,Horiuchi A,Hamamoto K,Iguchi C,Nakayama Y,Umemura T,Ichijo T,Matsumoto A,Yoshizawa K,Aoyama T,Tanaka E.Nonalcoholic fatty liver disease in Japanese junior high school students:its prevalence and relationship to lifestyle habits.J Gastroenterol 2010;45:666-672[PMID:20084525 DOI:10.1007/s00535-009-0198-4]
16 Berentzen TL,Gamborg M,Holst C,S?rensen TI,Baker JL.Body mass index in childhood and adult risk of primary liver cancer.J Hepatol 2014;60:325-330[PMID:24076363 DOI:10.1016/j.jhep.2013.09.015]
17 Buzzetti E,Pinzani M,Tsochatzis EA.The multiple-hit pathogenesis of non-alcoholic fatty liver disease(NAFLD).Metabolism 2016;65:1038-1048[PMID:26823198 DOI:10.1016/j.metabol.2015.12.012]
18 Tanaka N,Aoyama T,Kimura S,Gonzalez FJ.Targeting nuclear receptors for the treatment of fatty liver disease.Pharmacol Ther 2017;179:142-157[PMID:28546081 DOI:10.1016/j.pharmthera.2017.05.011]
19 Matsusue K,Kusakabe T,Noguchi T,Takiguchi S,Suzuki T,Yamano S,Gonzalez FJ.Hepatic steatosis in leptin-deficient mice is promoted by the PPARgamma target gene Fsp27.Cell Metab2008;7:302-311[PMID:18396136 DOI:10.1016/j.cmet.2008.03.003]
20 Donnelly KL,Smith CI,Schwarzenberg SJ,Jessurun J,Boldt MD,Parks EJ.Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease.JClin Invest 2005;115:1343-1351[PMID:15864352 DOI:10.1172/JCI23621]
21 Tanaka N,Takahashi S,Matsubara T,Jiang C,Sakamoto W,Chanturiya T,Teng R,Gavrilova O,Gonzalez FJ.Adipocyte-specific disruption of fat-specific protein 27 causes hepatosteatosis and insulin resistance in high-fat diet-fed mice.J Biol Chem 2015;290:3092-3105[PMID:25477509DOI:10.1074/jbc.M114.605980]
22 Tanaka N,Takahashi S,Fang ZZ,Matsubara T,Krausz KW,Qu A,Gonzalez FJ.Role of white adipose lipolysis in the development of NASH induced by methionine-and choline-deficient diet.Biochim Biophys Acta 2014;1841:1596-1607[PMID:25178843 DOI:10.1016/j.bbalip.2014.08.015]
23 Safar Zadeh E,Lungu AO,Cochran EK,Brown RJ,Ghany MG,Heller T,Kleiner DE,Gorden P.The liver diseases of lipodystrophy:the long-term effect of leptin treatment.J Hepatol 2013;59:131-137[PMID:23439261 DOI:10.1016/j.jhep.2013.02.007]
24 Rubio-Cabezas O,Puri V,Murano I,Saudek V,Semple RK,Dash S,Hyden CS,Bottomley W,Vigouroux C,MagréJ,Raymond-Barker P,Murgatroyd PR,Chawla A,Skepper JN,Chatterjee VK,Suliman S,Patch AM,Agarwal AK,Garg A,Barroso I,Cinti S,Czech MP,Argente J,O’Rahilly S,Savage DB;LD Screening Consortium.Partial lipodystrophy and insulin resistant diabetes in a patient with a homozygous nonsense mutation in CIDEC.EMBO Mol Med 2009;1:280-287[PMID:20049731 DOI:10.1002/emmm.200900037]
25 Tanaka N,Takahashi S,Zhang Y,Krausz KW,Smith PB,Patterson AD,Gonzalez FJ.Role of fibroblast growth factor 21 in the early stage of NASH induced by methionine-and cholinedeficient diet.Biochim Biophys Acta 2015;1852:1242-1252[PMID:25736301 DOI:10.1016/j.bbadis.2015.02.012]
26 Tanaka N,Takahashi S,Hu X,Lu Y,Fujimori N,Golla S,Fang ZZ,Aoyama T,Krausz KW,Gonzalez FJ.Growth arrest and DNA damage-inducible 45αprotects against nonalcoholic steatohepatitis induced by methionine-and choline-deficient diet.Biochim Biophys Acta Mol Basis Dis 2017;1863:3170-3182[PMID:28844958 DOI:10.1016/j.bbadis.2017.08.017]
27 Akazawa Y,Nakao K.To die or not to die:death signaling in nonalcoholic fatty liver disease.JGastroenterol 2018;53:893-906[PMID:29574534 DOI:10.1007/s00535-018-1451-5]
28 Jiang C,Xie C,Li F,Zhang L,Nichols RG,Krausz KW,Cai J,Qi Y,Fang ZZ,Takahashi S,Tanaka N,Desai D,Amin SG,Albert I,Patterson AD,Gonzalez FJ.Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.J Clin Invest 2015;125:386-402[PMID:25500885 DOI:10.1172/JCI76738]
29 Gan LT,Van Rooyen DM,Koina ME,McCuskey RS,Teoh NC,Farrell GC.Hepatocyte free cholesterol lipotoxicity results from JNK1-mediated mitochondrial injury and is HMGB1 and TLR4-dependent.J Hepatol 2014;61:1376-1384[PMID:25064435 DOI:10.1016/j.jhep.2014.07.024]
30 Zhang L,Nichols RG,Correll J,Murray IA,Tanaka N,Smith PB,Hubbard TD,Sebastian A,Albert I,Hatzakis E,Gonzalez FJ,Perdew GH,Patterson AD.Persistent Organic Pollutants Modify Gut Microbiota-Host Metabolic Homeostasis in Mice Through Aryl Hydrocarbon Receptor Activation.Environ Health Perspect 2015;123:679-688[PMID:25768209 DOI:10.1289/ehp.1409055]
31 Chu H,Duan Y,Yang L,Schnabl B.Small metabolites,possible big changes:a microbiotacentered view of non-alcoholic fatty liver disease.Gut 2018[PMID:30171065 DOI:10.1136/gutjnl-2018-316307]
32 Lee YA,Wallace MC,Friedman SL.Pathobiology of liver fibrosis:a translational success story.Gut 2015;64:830-841[PMID:25681399 DOI:10.1136/gutjnl-2014-306842]
33 Saitta C,Tripodi G,Barbera A,Bertuccio A,Smedile A,Ciancio A,Raffa G,Sangiovanni A,Navarra G,Raimondo G,Pollicino T.Hepatitis B virus(HBV)DNA integration in patients with occult HBV infection and hepatocellular carcinoma.Liver Int 2015;35:2311-2317[PMID:25677098 DOI:10.1111/liv.12807]
34 Kimura T,Kobayashi A,Tanaka N,Sano K,Komatsu M,Fujimori N,Yamazaki T,Shibata S,Ichikawa Y,Joshita S,Umemura T,Matsumoto A,Horiuchi A,Mori H,Wada S,Kiyosawa K,Miyagawa SI,Tanaka E.Clinicopathological characteristics of non-B non-C hepatocellular carcinoma without past hepatitis B virus infection.Hepatol Res 2017;47:405-418[PMID:27288988DOI:10.1111/hepr.12762]
35 Wong CR,Nguyen MH,Lim JK.Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease.World J Gastroenterol 2016;22:8294-8303[PMID:27729736 DOI:10.3748/wjg.v22.i37.8294]
36 Younes R,Bugianesi E.Should we undertake surveillance for HCC in patients with NAFLD?JHepatol 2018;68:326-334[PMID:29122695 DOI:10.1016/j.jhep.2017.10.006]
37 Tanaka N,Horiuchi A,Yokoyama T,Kaneko G,Horigome N,Yamaura T,Nagaya T,Komatsu M,Sano K,Miyagawa S,Aoyama T,Tanaka E.Clinical characteristics of de novo nonalcoholic fatty liver disease following pancreaticoduodenectomy.J Gastroenterol 2011;46:758-768[PMID:21267748 DOI:10.1007/s00535-011-0370-5]
38 Nagaya T,Tanaka N,Kimura T,Kitabatake H,Fujimori N,Komatsu M,Horiuchi A,Yamaura T,Umemura T,Sano K,Gonzalez FJ,Aoyama T,Tanaka E.Mechanism of the development of nonalcoholic steatohepatitis after pancreaticoduodenectomy.BBA Clin 2015;3:168-174[PMID:26674248 DOI:10.1016/j.bbacli.2015.02.001]
39 Tanaka N,Yazaki M,Kobayashi K.A lean man with nonalcoholic fatty liver disease.Clin Gastroenterol Hepatol 2007;5:A32[PMID:16901765 DOI:10.1016/j.cgh.2006.06.014]
40 Komatsu M,Yazaki M,Tanaka N,Sano K,Hashimoto E,Takei Y,Song YZ,Tanaka E,Kiyosawa K,Saheki T,Aoyama T,Kobayashi K.Citrin deficiency as a cause of chronic liver disorder mimicking non-alcoholic fatty liver disease.J Hepatol 2008;49:810-820[PMID:18620775 DOI:10.1016/j.jhep.2008.05.016]
41 Komatsu M,Kimura T,Yazaki M,Tanaka N,Yang Y,Nakajima T,Horiuchi A,Fang ZZ,Joshita S,Matsumoto A,Umemura T,Tanaka E,Gonzalez FJ,Ikeda S,Aoyama T.Steatogenesis in adultonset type II citrullinemia is associated with down-regulation of PPARα.Biochim Biophys Acta2015;1852:473-481[PMID:25533124 DOI:10.1016/j.bbadis.2014.12.011]
42 Pericleous M,Kelly C,Wang T,Livingstone C,Ala A.Wolman’s disease and cholesteryl ester storage disorder:the phenotypic spectrum of lysosomal acid lipase deficiency.Lancet Gastroenterol Hepatol 2017;2:670-679[PMID:28786388 DOI:10.1016/S2468-1253(17)30052-3]
43 Tanaka N,Tanaka E,Sheena Y,Komatsu M,Okiyama W,Misawa N,Muto H,Umemura T,Ichijo T,Matsumoto A,Yoshizawa K,Horiuchi A,Kiyosawa K.Useful parameters for distinguishing nonalcoholic steatohepatitis with mild steatosis from cryptogenic chronic hepatitis in the Japanese population.Liver Int 2006;26:956-963[PMID:16953836 DOI:10.1111/j.1478-3231.2006.01338.x]
44 Kimura T,Tanaka N,Fujimori N,Sugiura A,Yamazaki T,Joshita S,Komatsu M,Umemura T,Matsumoto A,Tanaka E.Mild drinking habit is a risk factor for hepatocarcinogenesis in nonalcoholic fatty liver disease with advanced fibrosis.World J Gastroenterol 2018;24:1440-1450[PMID:29632425 DOI:10.3748/wjg.v24.i13.1440]
45 Li Q,Dhyani M,Grajo JR,Sirlin C,Samir AE.Current status of imaging in nonalcoholic fatty liver disease.World J Hepatol 2018;10:530-542[PMID:30190781 DOI:10.4254/wjh.v10.i8.530]
46 Zhang YN,Fowler KJ,Hamilton G,Cui JY,Sy EZ,Balanay M,Hooker JC,Szeverenyi N,Sirlin CB.Liver fat imaging-a clinical overview of ultrasound,CT,and MR imaging.Br J Radiol 2018;91:20170959[PMID:29722568 DOI:10.1259/bjr.20170959]
47 Hatta T,Fujinaga Y,Kadoya M,Ueda H,Murayama H,Kurozumi M,Ueda K,Komatsu M,Nagaya T,Joshita S,Kodama R,Tanaka E,Uehara T,Sano K,Tanaka N.Accurate and simple method for quantification of hepatic fat content using magnetic resonance imaging:a prospective study in biopsy-proven nonalcoholic fatty liver disease.J Gastroenterol 2010;45:1263-1271[PMID:20625773 DOI:10.1007/s00535-010-0277-6]
48 Fujimori N,Tanaka N,Shibata S,Sano K,Yamazaki T,Sekiguchi T,Kitabatake H,Ichikawa Y,Kimura T,Komatsu M,Umemura T,Matsumoto A,Tanaka E.Controlled attenuation parameter is correlated with actual hepatic fat content in patients with non-alcoholic fatty liver disease with none-to-mild obesity and liver fibrosis.Hepatol Res 2016;46:1019-1027[PMID:27183219 DOI:10.1111/hepr.12649]
49 Tanaka N,Ichijo T,Okiyama W,Mutou H,Misawa N,Matsumoto A,Yoshizawa K,Tanaka E,Kiyosawa K.Laparoscopic findings in patients with nonalcoholic steatohepatitis.Liver Int 2006;26:32-38[PMID:16420508 DOI:10.1111/j.1478-3231.2005.01198.x]
50 Brunt EM.Nonalcoholic fatty liver disease and the ongoing role of liver biopsy evaluation.Hepatol Commun 2017;1:370-378[PMID:29404465 DOI:10.1002/hep4.1055]
51 Tsutsui M,Tanaka N,Kawakubo M,Sheena Y,Horiuchi A,Komatsu M,Nagaya T,Joshita S,Umemura T,Ichijo T,Matsumoto A,Yoshizawa K,Aoyama T,Tanaka E,Sano K.Serum fragmented cytokeratin 18 levels reflect the histologic activity score of nonalcoholic fatty liver disease more accurately than serum alanine aminotransferase levels.J Clin Gastroenterol 2010;44:440-447[PMID:20104187 DOI:10.1097/MCG.0b013e3181bdefe2]
52 Tanaka N,Matsubara T,Krausz KW,Patterson AD,Gonzalez FJ.Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis.Hepatology 2012;56:118-129[PMID:22290395 DOI:10.1002/hep.25630]
53 Matsubara T,Tanaka N,Krausz KW,Manna SK,Kang DW,Anderson ER,Luecke H,Patterson AD,Shah YM,Gonzalez FJ.Metabolomics identifies an inflammatory cascade involved in dioxin-and diet-induced steatohepatitis.Cell Metab 2012;16:634-644[PMID:23140643 DOI:10.1016/j.cmet.2012.10.006]
54 Kitabatake H,Tanaka N,Fujimori N,Komatsu M,Okubo A,Kakegawa K,Kimura T,Sugiura A,Yamazaki T,Shibata S,Ichikawa Y,Joshita S,Umemura T,Matsumoto A,Koinuma M,Sano K,Aoyama T,Tanaka E.Association between endotoxemia and histological features of nonalcoholic fatty liver disease.World J Gastroenterol 2017;23:712-722[PMID:28216979 DOI:10.3748/wjg.v23.i4.712]
55 Enomoto H,Bando Y,Nakamura H,Nishiguchi S,Koga M.Liver fibrosis markers of nonalcoholic steatohepatitis.World J Gastroenterol 2015;21:7427-7435[PMID:26139988 DOI:10.3748/wjg.v21.i24.7427]
56 Angulo P,Kleiner DE,Dam-Larsen S,Adams LA,Bjornsson ES,Charatcharoenwitthaya P,Mills PR,Keach JC,Lafferty HD,Stahler A,Haflidadottir S,Bendtsen F.Liver Fibrosis,but No Other Histologic Features,Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.Gastroenterology 2015;149:389-397.e10[PMID:25935633 DOI:10.1053/j.gastro.2015.04.043]
57 Loomba R,Chalasani N.The Hierarchical Model of NAFLD:Prognostic Significance of Histologic Features in NASH.Gastroenterology 2015;149:278-281[PMID:26116800 DOI:10.1053/j.gastro.2015.06.016]
58 Yoneda M,Fujii H,Sumida Y,Hyogo H,Itoh Y,Ono M,Eguchi Y,Suzuki Y,Aoki N,Kanemasa K,Imajo K,Chayama K,Saibara T,Kawada N,Fujimoto K,Kohgo Y,Yoshikawa T,Okanoue T;Japan Study Group of Nonalcoholic Fatty Liver Disease.Platelet count for predicting fibrosis in nonalcoholic fatty liver disease.J Gastroenterol 2011;46:1300-1306[PMID:21750883 DOI:10.1007/s00535-011-0436-4]
59 Kaneda H,Hashimoto E,Yatsuji S,Tokushige K,Shiratori K.Hyaluronic acid levels can predict severe fibrosis and platelet counts can predict cirrhosis in patients with nonalcoholic fatty liver disease.J Gastroenterol Hepatol 2006;21:1459-1465[PMID:16911693 DOI:10.1111/j.1440-1746.2006.04447.x]
60 Ogawa Y,Honda Y,Kessoku T,Tomeno W,Imajo K,Yoneda M,Kawanaka M,Kirikoshi H,Ono M,Taguri M,Saito S,Yamanaka T,Wada K,Nakajima A.Wisteria floribunda agglutinin-positive Mac-2-binding protein and type 4 collagen 7S:useful markers for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease.J Gastroenterol Hepatol 2018;33:1795-1803[PMID:29633352 DOI:10.1111/jgh.14156]
61 Kamada T,Ono M,Hyogo H,Fujii H,Sumida Y,Yamada M,Mori K,Tanaka S,Maekawa T,Ebisutani Y,Yamamoto A,Takamatsu S,Yoneda M,Kawada N,Chayama K,Saibara T,Takehara T,Miyoshi E;Japan Study Group of Nonalcoholic Fatty Liver Disease(JSGNAFLD).Use of Mac-2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis.Hepatol Commun2017;1:780-791[PMID:29404494 DOI:10.1002/hep4.1080]
62 Atsukawa M,Tsubota A,Okubo T,Arai T,Nakagawa A,Itokawa N,Kondo C,Kato K,Hatori T,Hano H,Oikawa T,Emoto N,Abe M,Kage M,Iwakiri K.Serum Wisteria floribunda agglutininpositive Mac-2 binding protein more reliably distinguishes liver fibrosis stages in non-alcoholic fatty liver disease than serum Mac-2 binding protein.Hepatol Res 2018;48:424-432[PMID:29274190 DOI:10.1111/hepr.13046]
63 Fujimori N,Umemura T,Kimura T,Tanaka N,Sugiura A,Yamazaki T,Joshita S,Komatsu M,Usami Y,Sano K,Igarashi K,Matsumoto A,Tanaka E.Serum autotaxin levels are correlated with hepatic fibrosis and ballooning in patients with non-alcoholic fatty liver disease.World JGastroenterol 2018;24:1239-1249[PMID:29568204 DOI:10.3748/wjg.v24.i11.1239]
64 Angulo P,Hui JM,Marchesini G,Bugianesi E,George J,Farrell GC,Enders F,Saksena S,Burt AD,Bida JP,Lindor K,Sanderson SO,Lenzi M,Adams LA,Kench J,Therneau TM,Day CP.The NAFLD fibrosis score:a noninvasive system that identifies liver fibrosis in patients with NAFLD.Hepatology 2007;45:846-854[PMID:17393509 DOI:10.1002/hep.21496]
65 Peleg N,Issachar A,Sneh-Arbib O,Shlomai A.AST to Platelet Ratio Index and fibrosis 4calculator scores for non-invasive assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease.Dig Liver Dis 2017;49:1133-1138[PMID:28572039 DOI:10.1016/j.dld.2017.05.002]
66 Sumida Y,Yoneda M,Hyogo H,Itoh Y,Ono M,Fujii H,Eguchi Y,Suzuki Y,Aoki N,Kanemasa K,Fujita K,Chayama K,Saibara T,Kawada N,Fujimoto K,Kohgo Y,Yoshikawa T,Okanoue T;Japan Study Group of Nonalcoholic Fatty Liver Disease(JSG-NAFLD).Validation of the FIB4index in a Japanese nonalcoholic fatty liver disease population.BMC Gastroenterol 2012;12:2[PMID:22221544 DOI:10.1186/1471-230X-12-2]
67 Harrison SA,Oliver D,Arnold HL,Gogia S,Neuschwander-Tetri BA.Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease.Gut 2008;57:1441-1447[PMID:18390575 DOI:10.1136/gut.2007.146019]
68 Okanoue T,Ebise H,Kai T,Mizuno M,Shima T,Ichihara J,Aoki M.A simple scoring system using type IV collagen 7S and aspartate aminotransferase for diagnosing nonalcoholic steatohepatitis and related fibrosis.J Gastroenterol 2018;53:129-139[PMID:28589339 DOI:10.1007/s00535-017-1355-9]
69 Guha IN,Parkes J,Roderick P,Chattopadhyay D,Cross R,Harris S,Kaye P,Burt AD,Ryder SD,Aithal GP,Day CP,Rosenberg WM.Noninvasive markers of fibrosis in nonalcoholic fatty liver disease:Validating the European Liver Fibrosis Panel and exploring simple markers.Hepatology2008;47:455-460[PMID:18038452 DOI:10.1002/hep.21984]
70 Ratziu V,Massard J,Charlotte F,Messous D,Imbert-Bismut F,Bonyhay L,Tahiri M,Munteanu M,Thabut D,Cadranel JF,Le Bail B,de Ledinghen V,Poynard T;LIDO Study Group;CYTOLstudy group.Diagnostic value of biochemical markers(FibroTest-FibroSURE)for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease.BMC Gastroenterol 2006;6:6[PMID:16503961 DOI:10.1186/1471-230X-6-6]
71 Sumida Y,Nakajima A,Itoh Y.Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.World JGastroenterol 2014;20:475-485[PMID:24574716 DOI:10.3748/wjg.v20.i2.475]
72 Hsu C,Caussy C,Imajo K,Chen J,Singh S,Kaulback K,Le MD,Hooker J,Tu X,Bettencourt R,Yin M,Sirlin CB,Ehman RL,Nakajima A,Loomba R.Magnetic Resonance vs Transient Elastography Analysis of Patients With Nonalcoholic Fatty Liver Disease:A Systematic Review and Pooled Analysis of Individual Participants.Clin Gastroenterol Hepatol 2018[PMID:29908362DOI:10.1016/j.cgh.2018.05.059]
73 Vilar-Gomez E,Yasells-Garcia A,Martinez-Perez Y,Calzadilla-Bertot L,Torres-Gonzalez A,Gra-Oramas B,Gonzalez-Fabian L,Villa-Jimenez O,Friedman SL,Diago M,Romero-Gomez M.Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention.Hepatology 2016;63:1875-1887[PMID:26849287 DOI:10.1002/hep.28484]
74 Romero-Gómez M,Zelber-Sagi S,Trenell M.Treatment of NAFLD with diet,physical activity and exercise.J Hepatol 2017;67:829-846[PMID:28545937 DOI:10.1016/j.jhep.2017.05.016]
75 Marchesini G,Petta S,Dalle Grave R.Diet,weight loss,and liver health in nonalcoholic fatty liver disease:Pathophysiology,evidence,and practice.Hepatology 2016;63:2032-2043[PMID:26663351 DOI:10.1002/hep.28392]
76 von Sch?nfels W,Beckmann JH,Ahrens M,Hendricks A,R?cken C,Szymczak S,Hampe J,Schafmayer C.Histologic improvement of NAFLD in patients with obesity after bariatric surgery based on standardized NAS(NAFLD activity score).Surg Obes Relat Dis 2018;14:1607-1616[PMID:30146425 DOI:10.1016/j.soard.2018.07.012]
77 Watanabe S,Hashimoto E,Ikejima K,Uto H,Ono M,Sumida Y,Seike M,Takei Y,Takehara T,Tokushige K,Nakajima A,Yoneda M,Saibara T,Shiota G,Sakaida I,Nakamuta M,Mizuta T,Tsubouchi H,Sugano K,Shimosegawa T;Japanese Society of Gastroenterology;Japan Society of Hepatology.Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.J Gastroenterol 2015;50:364-377[PMID:25708290 DOI:10.1007/s00535-015-1050-7]
78 Younossi Z,Tacke F,Arrese M,Sharma BC,Mostafa I,Bugianesi E,Wong VW,Yilmaz Y,George J,Fan J,Vos MB.Global Perspectives on Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis.Hepatology 2018[PMID:30179269 DOI:10.1002/hep.30251]
79 Sanyal AJ,Chalasani N,Kowdley KV,McCullough A,Diehl AM,Bass NM,Neuschwander-Tetri BA,Lavine JE,Tonascia J,Unalp A,Van Natta M,Clark J,Brunt EM,Kleiner DE,Hoofnagle JH,Robuck PR;NASH CRN.Pioglitazone,vitamin E,or placebo for nonalcoholic steatohepatitis.NEngl J Med 2010;362:1675-1685[PMID:20427778 DOI:10.1056/NEJMoa0907929]
80 Cusi K,Orsak B,Bril F,Lomonaco R,Hecht J,Ortiz-Lopez C,Tio F,Hardies J,Darland C,Musi N,Webb A,Portillo-Sanchez P.Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus:A Randomized Trial.Ann Intern Med 2016;165:305-315[PMID:27322798 DOI:10.7326/M15-1774]
81 Huang MY,Chung CH,Chang WK,Lin CS,Chen KW,Hsieh TY,Chien WC,Lin HH.The role of thiazolidinediones in hepatocellular carcinoma risk reduction:a population-based cohort study in Taiwan.Am J Cancer Res 2017;7:1606-1616[PMID:28744408]
82 Portillo-Sanchez P,Bril F,Lomonaco R,Barb D,Orsak B,Bruder JM,Cusi K.Effect of pioglitazone on bone mineral density in patients with nonalcoholic steatohepatitis:A 36-month clinical trial.J Diabetes 2018[PMID:30073778 DOI:10.1111/1753-0407.12833]
83 Sumida Y,Yoneda M.Current and future pharmacological therapies for NAFLD/NASH.JGastroenterol 2018;53:362-376[PMID:29247356 DOI:10.1007/s00535-017-1415-1]
84 Neuschwander-Tetri BA,Loomba R,Sanyal AJ,Lavine JE,Van Natta ML,Abdelmalek MF,Chalasani N,Dasarathy S,Diehl AM,Hameed B,Kowdley KV,McCullough A,Terrault N,Clark JM,Tonascia J,Brunt EM,Kleiner DE,Doo E;NASH Clinical Research Network.Farnesoid Xnuclear receptor ligand obeticholic acid for non-cirrhotic,non-alcoholic steatohepatitis(FLINT):a multicentre,randomised,placebo-controlled trial.Lancet 2015;385:956-965[PMID:25468160DOI:10.1016/S0140-6736(14)61933-4]
85 Ratziu V,Harrison SA,Francque S,Bedossa P,Lehert P,Serfaty L,Romero-Gomez M,Boursier J,Abdelmalek M,Caldwell S,Drenth J,Anstee QM,Hum D,Hanf R,Megnien S,Staels B,Sanyal A;GOLDEN-505 Investigator Study Group.Elafibranor,an Agonist of the Peroxisome Proliferator-Activated Receptor-αand-δ,Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.Gastroenterology 2016;150:1147-1159.e5[PMID:26874076 DOI:10.1053/j.gastro.2016.01.038]
86 Wang PX,Ji YX,Zhang XJ,Zhao LP,Yan ZZ,Zhang P,Shen LJ,Yang X,Fang J,Tian S,Zhu XY,Gong J,Zhang X,Wei QF,Wang Y,Li J,Wan L,Xie Q,She ZG,Wang Z,Huang Z,Li H.Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates.Nat Med 2017;23:439-449[PMID:28218919 DOI:10.1038/nm.4290]
87 Schuster S,Feldstein AE.NASH:Novel therapeutic strategies targeting ASK1 in NASH.Nat Rev Gastroenterol Hepatol 2017;14:329-330[PMID:28377639 DOI:10.1038/nrgastro.2017.42]
88 Friedman SL,Ratziu V,Harrison SA,Abdelmalek MF,Aithal GP,Caballeria J,Francque S,Farrell G,Kowdley KV,Craxi A,Simon K,Fischer L,Melchor-Khan L,Vest J,Wiens BL,Vig P,Seyedkazemi S,Goodman Z,Wong VW,Loomba R,Tacke F,Sanyal A,Lefebvre E.Arandomized,placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis.Hepatology 2018;67:1754-1767[PMID:28833331 DOI:10.1002/hep.29477]
89 Akuta N,Watanabe C,Kawamura Y,Arase Y,Saitoh S,Fujiyama S,Sezaki H,Hosaka T,Kobayashi M,Kobayashi M,Suzuki Y,Suzuki F,Ikeda K,Kumada H.Effects of a sodiumglucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus:Preliminary prospective study based on serial liver biopsies.Hepatol Commun 2017;1:46-52[PMID:29404432 DOI:10.1002/hep4.1019]
90 Sanyal A,Charles ED,Neuschwander-Tetri BA,Loomba R,Harrison SA,Abdelmalek MF,Lawitz EJ,Halegoua-DeMarzio D,Kundu S,Noviello S,Luo Y,Christian R.Pegbelfermin(BMS-986036),a PEGylated fibroblast growth factor 21 analogue,in patients with non-alcoholic steatohepatitis:a randomised,double-blind,placebo-controlled,phase 2a trial.Lancet 2018[PMID:30554783 DOI:10.1016/S0140-6736(18)31785-9]
91 Barreyro FJ,Holod S,Finocchietto PV,Camino AM,Aquino JB,Avagnina A,Carreras MC,Poderoso JJ,Gores GJ.The pan-caspase inhibitor Emricasan(IDN-6556)decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis.Liver Int 2015;35:953-966[PMID:24750664 DOI:10.1111/liv.12570]
92 Harrison SA,Marri SR,Chalasani N,Kohli R,Aronstein W,Thompson GA,Irish W,Miles MV,Xanthakos SA,Lawitz E,Noureddin M,Schiano TD,Siddiqui M,Sanyal A,Neuschwander-Tetri BA,Traber PG.Randomised clinical study:GR-MD-02,a galectin-3 inhibitor,vs.placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis.Aliment Pharmacol Ther2016;44:1183-1198[PMID:27778367 DOI:10.1111/apt.13816]
93 Birukawa NK,Murase K,Sato Y,Kosaka A,Yoneda A,Nishita H,Fujita R,Nishimura M,Ninomiya T,Kajiwara K,Miyazaki M,Nakashima Y,Ota S,Murakami Y,Tanaka Y,Minomi K,Tamura Y,Niitsu Y.Activated hepatic stellate cells are dependent on self-collagen,cleaved by membrane type 1 matrix metalloproteinase for their growth.J Biol Chem 2014;289:20209-20221[PMID:24867951 DOI:10.1074/jbc.M113.544494]
94 Boursier J,Mueller O,Barret M,Machado M,Fizanne L,Araujo-Perez F,Guy CD,Seed PC,Rawls JF,David LA,Hunault G,Oberti F,Calès P,Diehl AM.The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota.Hepatology 2016;63:764-775[PMID:26600078 DOI:10.1002/hep.28356]
95 Da Silva HE,Teterina A,Comelli EM,Taibi A,Arendt BM,Fischer SE,Lou W,Allard JP.Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass index and insulin resistance.Sci Rep 2018;8:1466[PMID:29362454 DOI:10.1038/s41598-018-19753-9]
96 Rau M,Rehman A,Dittrich M,Groen AK,Hermanns HM,Seyfried F,Beyersdorf N,Dandekar T,Rosenstiel P,Geier A.Fecal SCFAs and SCFA-producing bacteria in gut microbiome of human NAFLD as a putative link to systemic T-cell activation and advanced disease.United European Gastroenterol J 2018;6:1496-1507[PMID:30574320 DOI:10.1177/2050640618804444]
97 Yoshimoto S,Loo TM,Atarashi K,Kanda H,Sato S,Oyadomari S,Iwakura Y,Oshima K,Morita H,Hattori M,Honda K,Ishikawa Y,Hara E,Ohtani N.Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome.Nature 2013;499:97-101[PMID:23803760DOI:10.1038/nature12347]
98 Tripathi A,Debelius J,Brenner DA,Karin M,Loomba R,Schnabl B,Knight R.The gut-liver axis and the intersection with the microbiome.Nat Rev Gastroenterol Hepatol 2018;15:397-411[PMID:29748586 DOI:10.1038/s41575-018-0011-z]
99 Alkhouri N,Poordad F,Lawitz E.Management of nonalcoholic fatty liver disease:Lessons learned from type 2 diabetes.Hepatol Commun 2018;2:778-785[PMID:30027137 DOI:10.1002/hep4.1195]
100 Nasr P,Ignatova S,Kechagias S,Ekstedt M.Natural history of nonalcoholic fatty liver disease:Aprospective follow-up study with serial biopsies.Hepatol Commun 2017;2:199-210[PMID:29404527 DOI:10.1002/hep4.1134]
101 Loomba R,Sanyal AJ,Kowdley KV,Terrault N,Chalasani NP,Abdelmalek MF,McCullough AJ,Shringarpure R,Ferguson B,Lee L,Chen J,Liberman A,Shapiro D,Neuschwander-Tetri BA.Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis.Gastroenterology 2019;156:88-95.e5[PMID:30222962 DOI:10.1053/j.gastro.2018.09.021]
102 Eslam M,Hashem AM,Romero-Gomez M,Berg T,Dore GJ,Mangia A,Chan HLY,Irving WL,Sheridan D,Abate ML,Adams LA,Weltman M,Bugianesi E,Spengler U,Shaker O,Fischer J,Mollison L,Cheng W,Nattermann J,Riordan S,Miele L,Kelaeng KS,Ampuero J,Ahlenstiel G,McLeod D,Powell E,Liddle C,Douglas MW,Booth DR,George J;International Liver Disease Genetics Consortium(ILDGC).FibroGENE:A gene-based model for staging liver fibrosis.JHepatol 2016;64:390-398[PMID:26592354 DOI:10.1016/j.jhep.2015.11.008]
103 Tanaka N,Sano K,Horiuchi A,Tanaka E,Kiyosawa K,Aoyama T.Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis.J Clin Gastroenterol 2008;42:413-418[PMID:18277895 DOI:10.1097/MCG.0b013e31815591aa]
104 Sumida Y,Murotani K,Saito M,Tamasawa A,Osonoi Y,Yoneda M,Osonoi T.Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease:A prospective,single-arm trial(LEAD trial).Hepatol Res 2018[PMID:30051943 DOI:10.1111/hepr.13236]
105 Komatsu M,Tanaka N,Kimura T,Fujimori N,Sano K,Horiuchi A,Sugiura A,Yamazaki T,Shibata S,Joshita S,Umemura T,Matsumoto A,Tanaka E.Miglitol attenuates non-alcoholic steatohepatitis in diabetic patients.Hepatol Res 2018;48:1092-1098[PMID:29935004 DOI:10.1111/hepr.13223]
106 Nagaya T,Tanaka N,Suzuki T,Sano K,Horiuchi A,Komatsu M,Nakajima T,Nishizawa T,Joshita S,Umemura T,Ichijo T,Matsumoto A,Yoshizawa K,Nakayama J,Tanaka E,Aoyama T.Down-regulation of SREBP-1c is associated with the development of burned-out NASH.J Hepatol2010;53:724-731[PMID:20655124 DOI:10.1016/j.jhep.2010.04.033]